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Abstract
Development and Characterization of a Bi-specific Antibody Targeting HLA-A2/PR1
Amanda Cernosek Herrmann, BS
Advisory Professor: Jeffrey Molldrem, MD

Despite substantial advances in the treatment of acute myeloid leukemia (AML),
only 30% of AML patients survive more than 5 years. Therefore, new therapeutics are
much needed. Here, we present novel therapeutic strategy targeting myeloid leukemia
antigen, HLA-A2 restricted peptide PR1.Previously, we have conducted pre-clinical
development and humanization of a T cell receptor-like monoclonal antibody (h8F4) that
targets PR1/HLA-A2 and eliminates AML xenografts by antibody-dependent cellular
cytotoxicity (ADCC) following repeat dosing. To improve the potency of h8F4, we have
developed a bi-specific T cell-engaging antibody that targets PR1/HLA-A2 on leukemia
and CD3 on neighboring T cells. Here we demonstrate successful production and
purification of the h8F4 bi-specific antibody. Utilizing flow cytometry, we confirm
PR1/HLA-A2 and CD3-specific binding characteristics, T cell activation in the presence
of PR1/HLA-A2, and importantly AML target cell cytotoxicity after h8F4 bi-specific
antibody engagement with healthy donor effector T cells. Cytotoxicity assays were
performed with both AML cell lines and primary patient AML blasts serving as target
cells and health donor PBMC as a source of effector T cells at an Effector: Target ratio of
2:1. Results indicate up to 50% leukemia-specific lysis with 0.2nM h8F4 bi-specific
antibody after only 18 hours of incubation. In addition, in vivo data also confirms
	
  

vii

significant elimination of the leukemia cell line U937 (as evidenced by % leukemia cells
detected in peripheral blood and bio-luminescence imaging) in an NSG-U937 AML
xenograft mouse model when compared to control groups treated with effector cells
alone. In conclusion, these studies demonstrate the therapeutic potential of a novel bispecific antibody targeting the PR1/HLA-A2 leukemia-associated antigen. This bispecific antibody appears to increase the potency of h8F4 with rapid elimination of AML
and our studies justify potential development as a treatment option for patients with highrisk AML.

	
  

viii

Table of Contents
Dedication ......................................................................................................................... iii
Acknowledgements .......................................................................................................... iv
Abstract............................................................................................................................ vii
Table of Contents ............................................................................................................. ix
List of Figures................................................................................................................... xi
List of Tables .................................................................................................................. xiii
Chapter 1: Introduction ................................................................................................... 1
Cancer and the Immune System ............................................................................................... 1
Acute Myeloid Leukemia ........................................................................................................... 2
Bi-specific T-cell Engaging Antibodies..................................................................................... 3
Leukemia-Associated Antigen PR1 .......................................................................................... 5
Hypothesis and Specific Aims ................................................................................................... 6

Chapter 2: h8F4 Bi-Specific Antibody Molecular Construction .................................. 9
Primers and PCR Assembly .................................................................................................... 10
Protein Structural Modeling ................................................................................................... 13

Chapter 3: Prokaryotic production and initial characterization ............................... 15
Bacterial Culturing .................................................................................................................. 15
Harvesting and Purification .................................................................................................... 16
Alternate Constructs ................................................................................................................ 18
Functional Studies .................................................................................................................... 18

Chapter 4: Eukaryotic Production and Purification ................................................... 23

	
  

ix

Expression System Development ............................................................................................ 23
Histidine Tag Purification ....................................................................................................... 23
FPLC Size Exclusion Chromatography ................................................................................. 27

Chapter 5: In vitro functional analysis .......................................................................... 30
Cell surface binding assessment .............................................................................................. 30
Bio-layer Interferometry ......................................................................................................... 37
Anti-idiotype antibody ELISA ................................................................................................ 39
Co-culture experiments – AML Cell Lines ............................................................................ 41
Flow Cytometry and Cytokine ELISA: T-cell Activation ..................................................... 41
Cytotoxicity Analysis ............................................................................................................ 45
Co-Culture experiments- Primary Patient AML Samples ................................................... 48
Patient Profiles ....................................................................................................................... 48
Flow Cytometry for T-cell Activation ................................................................................... 50
Cytotoxicity Analysis ............................................................................................................ 52

Chapter 6: In vivo functional analysis........................................................................... 54
Background ............................................................................................................................... 54
Materials and treatment schedule .......................................................................................... 55
Results ....................................................................................................................................... 57

Chapter 7: Discussion and Future Directions .............................................................. 67
Bibliography .................................................................................................................... 74
Vita ................................................................................................................................... 85

	
  

x

List of Figures
FIGURE 1: SCHEMATIC OVERVIEW OF H8F4 BI-SPECIFIC ANTIBODY CONSTRUCTION AND
FUNCTIONALITY. .............................................................................................................................. 7
FIGURE 2: SCHEMATIC DIAGRAM OF THE SOLUBLE H8F4 BI-SPECIFIC ANTIBODY. ................ 9
FIGURE 3: SUMMARY OF DNA CONSTRUCTION OF H8F4 BI-SPECIFIC ANTIBODY .................. 12
FIGURE 4: THEORETICAL MODELING OF THE H8F4 PORTION OF THE BI-SPECIFIC
ANTIBODY ......................................................................................................................................... 14
FIGURE 5: SDS-PAGE SUMMARY OF PROKARYOTIC H8F4 BI-SPECIFIC ANTIBODY
PRODUCTION AND PURIFICATION ............................................................................................. 17
FIGURE 6: SURFACE BINDING H8F4 BI-SPECIFIC ANTIBODY PRODUCED IN A PROKARYOTIC
SYSTEM. ............................................................................................................................................. 20
FIGURE 7: EVALUATION OF PROKARYOTIC H8F4 BI-SPECIFIC ANTIBODY HLA-A2/PR1 AND
CD3 BINDING SPECIFICITY ........................................................................................................... 22
FIGURE 8: SCHEMATIC OUTLINING EUKARYOTIC EXPRESSION SYSTEM ................................. 24
FIGURE 9: SDS-PAGE AND COOMASSIE STAIN OF EUKARYOTIC ANTIBODY PRODUCTION 25
FIGURE 10: SDS-PAGE AND COOMASSIE STAIN OF EUKARYOTIC ANTIBODY PRODUCTION
.............................................................................................................................................................. 26
FIGURE 11: SIZE-EXCLUSION FPLC OF SOLUBLE H8F4 BI-SPECIFIC ANTIBODY ...................... 28
FIGURE 12: CONFIRMATION OF ISOLATED MONOMERIC H8F4 BI-SPECIFIC ANTIBODY ...... 29
FIGURE 13: FLOW CYTOMETRY ANALYSIS OF H8F4 BI-SPECIFIC ANTIBODY BINDING OF
CD3+ ..................................................................................................................................................... 32
FIGURE 14: FLOW CYTOMETRY ANALYSIS OF H8F4 BI-SPECIFIC ANTIBODY BINDING OF
HLA-A2/PR1 ....................................................................................................................................... 34
FIGURE 15: EVALUATION OF ANTIGEN BINDING SIMILARITIES BETWEEN PARENT H8F4
ANTIBODY AND H8F4 BI-SPECIFIC ANTIBODY ........................................................................ 36
FIGURE 16: BIO-LAYER INTERFEROMETRY ANALYSIS OF H8F4 BI-SPECIFIC ANTIBODY
BINDING ............................................................................................................................................. 38
FIGURE 17: ANTI-IDIOTYPE ELISA ........................................................................................................ 40

	
  

xi

FIGURE 18: H8F4 BI-SPECIFIC ANTIBODY INDUCES T-CELL ACTIVATION FOLLOWING COCULTURE WITH THP1 AML CELL LINE ...................................................................................... 43
FIGURE 19: CYTOKINE PRODUCTION FOLLOWING H8F4 BI-SPECIFIC ANTIBODY T-CELL
ACTIVATION ..................................................................................................................................... 44
FIGURE 20: REDIRECTED CYTOTOXICITY OF T CELLS AGAINST HLA-A2/PR1+ CELL LINE
THP1 .................................................................................................................................................... 46
FIGURE 21: REDIRECTED CYTOTOXICITY OF T-CELLS TOWARDS AML CELL LINE U937 ..... 47
FIGURE 22: H8F4 BI-SPECIFIC ANTIBODY INDUCES T-CELL ACTIVATION FOLLOWING COCULTURE WITH PRIMARY AML PATIENT SAMPLES .............................................................. 51
FIGURE 23: H8F4 BI-SPECIFIC ANTIBODY REDIRECTS CYTOTOXICITY OF T-CELLS
TOWARDS HLA-A2+ PRIMARY AML BLASTS ............................................................................ 52
FIGURE 24: EXPERIMENTAL OUTLINE FOR IN VIVO EVALUATION OF H8F4 BI-SPECIFIC
ANTIBODY TREATMENT OF AML ................................................................................................ 56
FIGURE 25: VISUAL SUMMARY OF BIO-LUMINESCENCE DATA FOR FIRST 21 DAYS OF IN
VIVO EXPERIMENT .......................................................................................................................... 58
FIGURE 26: QUANTITATIVE ASSESSMENT OF U937A2+ AML ENGRAFTMENT AS ASSESSED
BY

BIO-LUMINESCENCE

IMAGING

FOLLOWING

H8F4

BI-SPECIFIC

ANTIBODY

TREATMENT ..................................................................................................................................... 59
FIGURE 27: PERCENTAGE OF PERIPHERAL T-CELLS FOLLOWING H8F4 BI-SPECIFIC
ANTIBODY TREATMENT ................................................................................................................ 62
FIGURE 28: QUANTITATIVE ASSESSMENT OF U937A2+ AML ENGRAFTMENT AS ASSESSED
BY BIO-LUMINESCENCE IMAGING FOLLOWING H8F4 ANTIBODY TREATMENT. .......... 63
FIGURE 29: FLOW CYTOMETRY ANALYSIS OF U937 AML ENGRAFTMENT FOLLOWING H8F4
ANTIBODY THERAPY. .................................................................................................................... 64
FIGURE 30: KAPLAN-MEIER SURVIVAL ESTIMATE FOR IN VIVO TREATMENT WITH H8F4 BISPECIFIC ANTIBODY. ...................................................................................................................... 66

	
  

xii

List of Tables
TABLE 1: SUMMARY OF CLINICAL CHARACTERISTICS FOR AML PATIENT SAMPLES .......... 49

	
  

xiii

Chapter 1: Introduction
Cancer and the Immune System
The immune system is composed of two fundamental branches; the innate
immune system, which recognizes pathogen patterns and serves as an early response
system, and the adaptive immune system, composed primarily of B-cells and T-cells,
which respond to antigen presentation within lymphoid organs, resulting in clonal
expansion and eventual removal of the threat. These systems work together to protect the
body from a variety of threats, ranging from pathogens to cancer. Both systems play a
key role in the recognition and prevention of malignancy. Natural killer cells, as part of
the innate immune system, initially recognize abnormal cells and target their destruction,
leading to antigen presentation to B-cells and T-cells via macrophages and dendritic cells
within secondary lymphoid organs (i.e. lymph nodes). This process is necessary for
generating an effective and lasting adaptive immune response targeting cancer (1).
Immuno-surveillance occurs when the immune system continually scans and
monitors the cells of the body for abnormalities in the form of tumor antigens presented
on the surface of the abnormal cells. These tumor antigens are absent or very minimally
expressed on normal cells (2). A primary mechanism leading to the spread of cancer is
immune escape (3), in which the cancer cell evades immune detection and proliferates
freely. Immune escape occurs for several reasons; down-regulation of surface tumor
antigen or changes to the patient’s immune system preventing effective elimination of the
cancer cell. This second scenario can occur via up-regulation of immune inhibitory
molecules on the tumor itself such as PD-L1 (4) or the tumor producing a
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microenvironment that fosters immune cell inhibition through elaboration of toxic
metabolites or suppressive cytokines (5, 6). Cancer researchers and immunologists have
worked hard to understand the complex dynamic between tumor cells and the immune
system, and have developed many therapies to exploit the power of the immune system
for the treatment of cancer. Immunotherapy augments a patient’s own immune system for
the treatment of their malignancy. Numerous mechanisms of cancer immunotherapy have
been explored, including monoclonal antibodies targeting known tumor antigens,
adoptive T-cell transfer, cancer vaccines, cytokine therapy, bone marrow transplantation,
and therapies modulating T cell activity (7). It is the goal of this work to outline the
development of a novel immunotherapy for the treatment of acute myloid leukemia
(AML), as an addition to the growing number therapeutics in the field of cancer
immunotherapy.

Acute Myeloid Leukemia
Acute myloid leukemia (AML) is the most common acute leukemia among the
adult population (8). Estimates from the National Institutes of Health Surveillance,
Epidemiology and End Results (SEER) Program predict over 21,000 new cases of AML
will be diagnosed this year, representing 1.3% of all newly diagnosed cancer. While this
number may seem small compared to other more prevalent diseases such as breast cancer
or lung cancer, both with estimates of over 220,000 new cases, AML is still a devastating
disease to many Americans, with a 5-year survival rate at a dismal 25% (9). Standard of
care therapy for newly diagnosed AML consists of highly intensive standard induction
chemotherapy therapy, followed by allogeneic hematopoietic stem cell transplant in
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certain cases. Advances in treatment strategies have been slowly progressing with
intensified chemotherapy regimens for younger patients, providing more durable
remission. However, this disease is characteristically a disease of the elderly, with a
median age at diagnosis of 65 years. Many AML patients have not benefitted from these
advances in chemotherapy regimens, as they often cannot tolerate these strengthened
chemotherapy protocols, and new treatment strategies for these patients are desperately
needed (10). In addition to alterations in chemotherapy regimens and safer stem cell
transplant protocols, innovative targeting therapies have expanded treatment possibilities
for AML patients. The emerging field of cancer immunotherapy has provided many
opportunities for the development of novel therapeutics, harnessing the power of the
patients’ own immune system and redirecting it to fight their malignancy. Patients with
AML have benefited from these advances, and a variety of agents targeting established
leukemia antigens have made their way to the clinics and are showing great promise in
effectively treating patients (11). These include the drug-linked antibody therapy
Gemtuzumab Ozogamicin, which is a monoclonal antibody targeting the leukemia
antigen CD33 linked to an anti-tumor agent which is cytotoxic to cells (12) as well as a
bi-specific T-cell engaging antibody targeting the same leukemia antigen CD33 (13).

Bi-specific T-cell Engaging Antibodies
Bi-specific antibodies have been in development since the 1980’s, when Kohler
and Milstein developed principles of antibody production and hybridoma technology
(14). Traditional antibodies produced by the body consist of both variable and constant
regions. Constant regions determine the antibody isotype (G, M, E, etc.), and in turn
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dictate the antibody’s function (1). Two heavy chains (55-70kD) and two light chains
(24kD) complete the antibody. Three hypervariable regions contained within each heavy
and light chain come together to create the antigen binding surface, unique to each
monoclonal antibody (15). Initially, bi-specific antibodies were produced either through
redox reactions at the hinge histidine residues, or through fusion of hybridomas. With the
development of DNA technology, bi-specific antibodies have taken on a new role, and
many new formats continue to develop (15).
Of these many new formats, the bi-specific T-cell engager (BiTE) antibody
format has had the most success in the clinic, and is well on its way to treating a variety
of cancers. The most prominent drug within this class is Amgen’s Blinatumomab for the
treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia
(Philadelphia chromosome-negative) and minimal residual disease-positive B-cell
precursor acute lymphoblastic leukemia (ALL). This drug is a single chain bi-specific
antibody targeting CD3 and CD19, and has greatly increased disease free survival in
patients with these malignancies (16).The advantage of this type of construct is that it
brings cancer cell and T-cell into close proximity and facilitates a transient link between
the cells, and creating a cytolytic synapse and ultimately cancer cell cytotoxicity via
perforin, granzyme, and apoptosis (17). Inspired by the success of Blinatumomab, others
have begun introducing similar constructs redirecting T-cells to known cancer antigens
(over 25 in development to date) such as EpCAM and CEA (15), and the AML antigens
CD33 (18) and oncoprotein WT1 (19). Studies presented here introduce a novel
therapeutic in the bi-specific T-cell engaging class of AML therapies targeting the
leukemia-associated antigen PR1.
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Leukemia-Associated Antigen PR1
Bone marrow transplantation in the setting of AML is successful primarily due to
the graft-versus-leukemia effect, during which donor cytotoxic T-cells target and destroy
leukemia and/or leukemia stem cells following transplantation. These T-cells target
specific leukemia antigens, and defining and developing targeted therapies towards these
antigens has been a major endeavor over the years. For successful development of a
targeted therapy towards a specific leukemia antigen, the antigen must be specific or
highly associated with leukemia; the antigen must be found frequently in AML and
preferably on leukemia stem cells as well; the antigen should have an oncogenic role; the
antigen should be recognized by the immune system; and finally the antigen should
confer benefit when targeted clinically (20).
The work of our group centers on the leukemia-associated antigen PR1. PR1 is a
human leukocyte antigen (HLA)-A2 restricted nonapeptide (VLQELNVTV), which is
derived from the serine proteases proteinase-3 (P3) and neutrophil elastase (NE). NE and
P3 are found within normal neutrophil azurophilic granules and in myeloid leukemia
blasts. Studies from our group have established the HLA-A2/PR1 complex as an
important leukemia-associated antigen, showing in the setting of chronic myloid
leukemia, patients who responded to IFN-α2b and bone marrow transplantation had
circulating HLA-A2/PR1 specific T-cells. In addition, adoptive transfer of PR1 cytotoxic
T-cells reduces AML burden in a xenograft mouse model (21, 22). A humanized TCRlike monoclonal antibody (h8F4) targeting the HLA-A2/PR1 complex has been
developed in our group and undergone testing in vitro and in vivo, showing complete and
durable treatment of human primary AML in xenograft mouse models (23, 24).

	
  

5

With the success of this therapeutic antibody, additional therapies have been
developed within our group based on the targeting ability of the h8F4 antibody, including
a chimeric antigen receptor (CAR) T-cell (25). In vivo studies of the h8F4 monoclonal
antibody show that the therapy effectively reduces leukemia burden in animals engrafted
with primary patient AML. Ultimately, however, the animals succumb to disease due to
intense CNS infiltration, which cannot be treated with a full-length antibody due to
restrictions of the blood brain barrier (24). Based on these findings, we decided to
enhance the therapeutic efficacy of the h8F4 antibody by developing a bi-specific T-cell
engaging antibody, targeting CD3 on T-cells and the HLA-A1/PR1 complex on AML.
Hypothesis and Specific Aims
We hypothesize that our bi-specific T-cell engaging (BiTE) antibody will
facilitate targeted T-cell therapy against the leukemia associated antigen PR1 by
engaging both HLA-A2/PR1 on the target cell and CD3 on the T-cell, leading to T-cell
activation and tumor cell lysis. We base this hypothesis on the clinical success of other Tcell engaging bi-specific antibodies in this class of therapeutics, and anticipate the h8F4
bi-specific antibody will have an advantage over the parent antibody, as others in this
class have demonstrated the ability to treat malignancy within the CNS, although through
undefined mechanisms (26). A schematic of this hypothesis is provided in Figure 1.
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Figure 1: Schematic overview of h8F4 bi-specific antibody construction and
functionality.
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To investigate the mechanisms of action and the potential clinical efficacy of the h8F4 bispecific antibody, we will:

AIM 1: Develop an efficient large-scale production strategy for the h8F4 bi-specific
antibody.

AIM 2: Evaluate in vitro functional activity of the h8F4 bi-specific antibody to mediate
PR1/HLA-A2 specific T-cell activation and cytotoxicity.

AIM3: Determine the therapeutic efficacy of the h8F4 bi-specific antibody against AML
in vivo.

Our goal is to confirm redirected cell-mediated cytotoxicity toward HLA-A2/PR1
expressing myeloid leukemia blasts in vitro and in vivo to provide pre-clinical
justification to develop this as a therapeutic approach for AML patients. Successful
completion of this work will result in a safer and more effective treatment option than
currently available therapies.
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Chapter 2: h8F4 Bi-Specific Antibody Molecular Construction
In order to create a single chain fragment containing both HLA-A2/PR1 targeting
regions and CD3 targeting regions, variable fragments from both h8F4 and OKT3 were
isolated and linked using custom primers and strategic PCR. OKT3 was chosen as the
source for CD3 targeting variable regions, as it is a well-characterized anti-human T-cell
targeting antibody with known mitogen activation activity. The antibody was this first
monoclonal antibody to be approved for clinical use in humans, and has been used as a
tool for T-cell stimulation in the laboratory for decades (27, 28). Figure 2 demonstrates a
schematic of the arrangement of different elements key to successful h8F4 bi-specific
antibody production, including a eukaryotic signal sequence at the N terminus to aide in
ER trafficking, and a hexa-Histidine Tag at the C terminus to aide with purification and
later detection of the construct for in vitro analysis.

Figure 2: Schematic diagram of the soluble h8F4 bi-specific antibody.
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Figure 2: Schematic diagram of the soluble h8F4 bi-specific antibody. Light chain
variable fragments (VL) and heavy chain variable fragments (VH) of h8F4 and murine
OKT3 are linked in tandem via flexible glycine-serine linkers of either 10 or 15 amino
acids. A His6Tag was included at the C terminus for purification.
Primers and PCR Assembly
First, the light chain variable region of the parent humanized 8F4 monoclonal
antibody

was

amplified

with

the

primers

5’Nhe1_sig_Hu8F4_VL

and

3’rev_Hu8F4_VL_G4S (a list of primer sequences has been included at the end of this
section), with the goal introducing an in frame Nhe1 restriction enzyme site (GCTAGC)
and a signal sequence (AGCACCACC) at the N terminus and a G4S overhang on the C
terminus. The heavy chain variable fragment was amplified with primers introducing a
G4S overhang on the N terminus 5’G4S_Hu8F4_VH and a G4S overhang on the C
terminus with 3’rev_Hu8F4_VH_G4S. All reactions were performed using Pfu DNA
polymerase purchased from G biosciences (cat# 786-817) and used according to
manufacturers instructions.
To isolate and amplify OKT3 variable fragments, OKT3 hybridomas were
purchased from ATCC, and cultured according to ATCC guidelines. Total RNA was
extracted from cells using a TRIzol reagent. mRNA was converted to cDNA, and VH and
VL fragments were amplified with primers 5'G4S_mOKT3_VH, , 5’G4S_mOKT3_VL,
and 3’rev_mOKT3_VL_TH_Xho1. These primers introduced sites at both ends of the
VH and VL fragments providing overhangs for the universal primer to link the fragments.
For both h8F4 and OKT3, VH and VL fragments were linked to create single chain
variable fragments (scFv), and finally these scFv fragments were linked in tandem to
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produce the final construct. An agarose gel image is provided in Figure 3 summarizing
this DNA construction.
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Figure 3: Summary of DNA construction of h8F4 bi-specific antibody

Figure 3: Agarose gel with DNA fragments summarizing the construction of the h8F4 bispecific antibody. Heavy and light chain variable fragments of h8F4 (red) and murine
OKT3 (green) were linked to create single chain variable fragments (scFv), which were
then linked in tandem to produce the final single chain h8F4 bi-specific antibody
construct (yellow). The final construct was 1500 base pairs in length. DNA ladder on in
far left column indicates size of DNA fragments in base pairs.
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Primers were as follows:
5’Nhe1_sig_Hu8F4_VL: GCTAGCACCACCATG
3’rev_Hu8F4_VL_G4S: TGATCCGCCTCCGCCTTTGATTT
5’G4S_Hu8F4_VH: GGCGGAGGCGGATCAGGAGTGCA
3’rev_Hu8F4_VH_G4S: CCCGCCTGAACCACCTGAAGAGA
5'G4S_mOKT3_VH: GGTGGTTCSGGCGGGCAGGTCCAGCTGCAG
3'rev_mOKT3_VH_G4S: TGATCCGCCTCCGCCTGAGGAGACTGTGAG
5’G4S_mOKT3_VL: GGTGGAGGAGGATCTCAAATTGT
3’rev_mOKT3_VL_TH_Xho1:
CTCGAGTTAGTGATGGTGATGGTGATGACTACCGCGTGGCACCAGGTTTATTT
CCAACTT
Universal

Linker_G4S_3:

GGCGGAGGCGGATCAGGAGGTGGAGGATCCGGTGGAGGAGGAT

Protein Structural Modeling
Following construction, theoretical protein modeling of the h8F4 bi-specific
antibody was conducted using the free online software SWISS-MODEL using previous
crystal structures of TCR-like antibody binding as a guide (29). A representative model
of the bi-specific antibody is included in Figure 4. This model was based off of published
structures of human IgG1 antibodies, and was chosen as a model as the h8F4 parent
antibody is of this antibody class.
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Figure 4: Theoretical modeling of the h8F4 portion of the bi-specific antibody

Figure 4: Theoretical modeling of the h8F4 portion of the bi-specific antibody fit to a
human IgG1 Fc model. The complementarity determining regions have been color coded
as indicated on the figure.
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Chapter 3: Prokaryotic production and initial characterization
As the h8F bi-specific antibody does not contain any glycosylation sites,
production in either prokaryotic or eukaryotic systems should result in the same final
product. For the first round of h8F4 bi-specific antibody production, a prokaryotic
expression system was developed, as early bi-specific antibody constructs were
successfully produced in these systems (30), and all materials for production were readily
available in our lab.

Bacterial Culturing
Once the DNA sequence of the antibody construct was confirmed, the DNA
fragment was cloned into the prokaryotic expression vector pet24a (Novagen #69749-3).
This particular vector contained a kanamycin resistance gene for selection of successful
transformants, and an inducible lacI operon for blue-white colony screening and IPTGinducible protein production. The final expression vector containing insert was
electroporated into bacterial production strain BL21(DE3) competent E. coli cells.
Successfully electroporated cells were selected on LB/kanamycin agar plates with
supplemented X-gal for blue-white colony selection. Following plasmid sequencing,
clones were expanded in LB/kanamycin broth for protein production. Terrific broth, an
enriched culture medium (31), with kanamycin was the final culture medium, and once
100mL cultures reached exponential phase at 0.8 OD600, protein production was induced
via IPTG. E. coli cells were then harvested several hours later. Pelleted cells contained
the h8F4 bi-specific antibody within inclusion bodies, and specific harvesting techniques
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were employed.
Harvesting and Purification
Pellets were incubated in lysis buffer (Tris-HCl/EDTA/NaCl/lysozyme) for 1
hour, followed by 3 rounds of sonication. Following sonication, the solution was
centrifuged for 20 minutes at 12,000 RPM. The resulting pellet was re-suspended in 8M
Urea plus Tris-HCl to dissolve inclusion bodies. Following another round of sonication
and pelleting, the final solution was subjected to column purification.
The solution containing h8F4 bi-specific antibody was applied to column
containing Ni-NTA agarose, and allowed to flow through with gravity. The column was
washed with 10mM imidazole in urea, followed by 1mL elutions with 200mM imidazole.
Figure 5 shows an SDS-PAGE summary of the column elutions, with western blot
confirmation of successful bi-specific antibody production and purification.
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Figure 5: SDS-PAGE summary of Prokaryotic h8F4 bi-specific antibody production
and purification

Figure 5: SDS-PAGE of h8F4 bi-specific antibody produced in a prokaryotic system.
Coomassie staining of the elutions from Ni-NTA chromatography purification (left) show
a major band of protein at 55kD, the predicted size of the antibody. Western blot
detection of the antibody with anti-HisTag-HRP shows major bands of HisTagged
protein at 55kD and 20kD, indicating there may be significant cleavage products in the
eluted fractions.
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After SDS-PAGE confirmed h8F4 bi-specific antibody was successfully eluted,
refolding techniques including dialysis were employed to remove urea and imidazole,
which would interfere with cell assays. The final antibody product was re-suspended in
PBS. These techniques were based on previous bacterial expression systems generating
single chain variable fragments (32).

Alternate Constructs
Two h8F4 bi-specific antibody constructs were developed in parallel, one with a
10 amino acid linker between VH and VL fragments in the 8F4 portion of the antibody,
and one construct with 15 amino acids at the same position. These linker lengths were
based on the activity of single chain variable fragments developed for the generation of
the 8F4 chimeric antigen receptor (CAR) T-cell, in which parallel CAR T-cells were
generated with both 10aa and 15aa linkers in parallel, with both showing HLA-A2/PR1
redirected cytotoxicity (25).

Functional Studies
The T2 cell line was utilized to test for antigen binding specificity. This cell line
is TAP (transporter associated with antigen processing)-deficient, meaning the cells have
reduced ability to process exogenous antigens, but retain the ability to present peptides in
the context of HLA-A2 on their surface. Thus these cells can easily be pulsed with
exogenous peptide and reliably present this peptide on the surface of the cell (33). For all
experiments discussed in this dissertation, T2 cells were pulsed with 20µg/mL peptides
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overnight and washed in large-volume PBS to remove exogenous peptide. Cells were
then stained with h8F4 bi-specific antibody, with secondary detection with anti-HisTag
APC-Cy/7 using flow cytometry. Figure 6 shows the results of this initial experiment,
demonstrating detectable h8F4 bi-specific antibody binding with both 10aa and 15aa
constructs tested.

	
  

19

Figure 6: Surface binding h8F4 bi-specific antibody produced in a prokaryotic
system.

Figure 6: Flow cytometry staining of pulsed T2 cells (top panel) and healthy donor
PBMC (bottom panel) with 20ug/mL h8F4 bi-specific antibody produced in prokaryotic
system, detected with anti-HisTag APC-Cy7. Comparable fluorescent shifts are detected
with 10aa (left) and 15aa (right) linked bi-specific antibodies.
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Following this initial experiment, evaluation of concentration-dependent antigen
specific binding to HLA-A2/PR1 binding was evaluated by detection of PR1-pulsed T2
cells as compared to control CMV-pp65 pulsed T2 cells. CD3 target specificity was
determined by evaluating Jurkat cell binding as compared to the mutant Jurkat cell line
J.RT3, which does not express CD3. Figure 7 shows the h8F4 bi-specific antibody has
concentration-dependent and antigen specific surface binding to both HLA-A2/PR1 and
CD3, for both 10aa and 15aa constructs.
After initial production and characterization from the prokaryotic production
system, it was also decided to solely pursue the 10 amino acid construct, as the two
constructs had comparable binding patterns, and the 10aa showed higher production
potential. It was also decided not to pursue this mode of h8F4 bi-specific antibody
production, as cleavage products were a major source of contamination in the final
product. Also, the harvesting and refolding process was labor-intensive compared to the
final yield. It was decided to establish a eukaryotic production system, as there would be
no refolding required, and this method of bi-specific antibody production is currently
utilized for clinical grade material.
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Figure 7: Evaluation of prokaryotic h8F4 bi-specific antibody HLA-A2/PR1 and
CD3 binding specificity

Figure 7: Prokaryotic binding summary for h8F4 bi-specific antibody. Mean
Fluorescence Intensity (MFI) is presented. The h8F4 bi -specific antibody produced in
the prokaryotic system has antigen specific binding to both HLA-A2/PR1 and CD3, as
assessed via flow cytometry.
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Chapter 4: Eukaryotic Production and Purification
Expression System Development
To first establish the eukaryotic expression system, the 10aa h8F4 bi-specific
antibody construct was inserted into the eukaryotic expression vector pcDNA3.1 and
proper in-frame insertion was confirmed. Figure 8 outlines the development of the
eukaryotic expression system. To start, Chinese Hamster Ovary (CHO) cells were
transfected with the h8F4 bi-specific antibody expression vector using lipofectamine
(Thermo Fisher Scientific, Waltham, MA) according to manufacturer’s instructions, and
stable transfectants were generated by G418 drug selection following limiting dilution
assays. Stable transfectants were grown in roller bottles, and recombinant protein was
purified from the culture using Nickel affinity chromatography as previously described
(34).

Histidine Tag Purification
Cell culture supernatant from actively producing CHO cultures was harvested,
dialyzed against PBS to remove any inhibitory components in the culture medium, and
filter sterilized. The solution was then allowed to flow through Nickel column at 4oC for
several days with gravity. Washes containing 10mM imidazole in PBS, followed by 1mL
elutions in 200mM imidazole in PBS followed. Figure 9 and Figure 10 show SDS-PAGE
results of this purification, with coomassie and western blot analysis, respectively. The
h8F4 bi-specific antibody was successfully produced in CHO cell supernatant at 400
µg/L.
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Figure 8: Schematic outlining eukaryotic expression system

Figure 8: Establishment of h8F4 bi-specific antibody eukaryotic production system. To
start, the eukaryotic expression vector was transfected into CHO cells, and G418 was
used to select stable producing cells. Single clones were isolated by limiting dilution
assays, and high-producing clones were identified for positive antibody cell surface
binding using automated flow cytometry. Following selection, clones were scaled up and
grown in roller bottle cultures. Supernatant from roller bottle cultures was harvested and
Nickel column purification was performed.
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Figure 9: SDS-PAGE and Coomassie stain of eukaryotic antibody production
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Figure 9: SDS-PAGE of elution fractions of h8F4 bi-specific antibody from immobilized
Nickel affinity chromatography. Each lane contains 15ul aliquot of indicated stage of
purification. Coomassie staining shows high protein content of various sizes in the initial
supernatant and flow through material, with a large focus of protein at the 55kD size.
This band appears to elute in the first 5 mL of elutions.
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Figure 10: SDS-PAGE and Coomassie stain of eukaryotic antibody production
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Figure 10: SDS-PAGE under reducing conditions of elution fractions of h8F4 bi-specific
antibody from immobilized Nickel affinity chromatography. Each lane contains 15ul
aliquot of indicated stage of purification. Western blot analysis probed with anti-HisTag
antibodies shows complete isolation of the HisTagged proteins at the expected size of
55kD, with no apparent cleavage products, as opposed to the prokaryotic system.
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FPLC Size Exclusion Chromatography
Subsequently, recombinant proteins were subjected to fast protein liquid
chromatography (FPLC) on a GE Superdex 75 10/300 GL column (GE Healthcare Life
Sciences, Pittsburgh, PA) to isolate monomeric h8F4 bi-specific antibody. Recombinant
proteins were electrophoresed to confirm the molecular weight using 10% SDS-PAGE
and stained with GelCode Blue Stain Reagent (Thermo Fisher Scientific, Waltham MA)
and western blot was performed to confirm the presence of 6xHistidine Tag using antiHisTag HRP antibody and Pierce ECL western blotting substrates (Thermo Fisher
Scientific, Waltham, MA) as described previously (30). Column elutions were pooled and
subjected to size exclusion FPLC for enrichment of monomeric h8F4 bi-specific
antibody. Figure 11 is a sample FPLC elution profile of h8F4 bi-specific antibody, and
demonstrates that a portion of the antibody did form large aggregates, which eluted at
7mL. The majority of the antibody eluted in monomeric form between 14mL and 18mL,
and confirmed with SDS-PAGE and coomassie staining and western blot (Figure 12).
The final product was tested for the presence of endotoxin using a Limulus Amebocyte
Lysate-based kit purchased from Thermo Scientific, and endotoxin levels were confirmed
to be < 10EU/mL, which falls within the acceptable range for maximum endotoxin levels
for vaccines and other therapeutics (35).
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Figure 11: Size-exclusion FPLC of soluble h8F4 bi-specific antibody
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Figure 11: Fast liquid protein chromatography of soluble h8F4 bi-specific antibody
following immobilized Nickel affinity chromatography. Y axis represents OD 280
protein concentration. Based on expected size and elution volumes, two major peaks were
identified as oligomeric aggregates and monomeric h8F4 bi-specific antibody.
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Figure 12: Confirmation of isolated monomeric h8F4 bi-specific antibody

]

Figure 12: (Left) SDS-PAGE of purified monomeric h8F4 bi-specific antibody. 2, 1.5,
and 0.5µg of h8F4 bi-specific antibody was electrophoresed in a 10% polyacrylamide gel
under reducing conditions, and detected using coomassie die. (Right) Western blot of
monomeric h8F4 bi-specific antibody electrophoresed in a 10% polyacrylamide gel under
reducing conditions detected by anti-HisTag antibodies.
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Chapter 5: In vitro functional analysis
Cell surface binding assessment
Initial characterization of the h8F4 bi-specific antibody began with determination
of the antibody’s antigen recognition specificity. This is a crucial component for moving
this therapeutic safely to the clinic (36), as this class of immunotherapy is extremely
potent, with the ability to produce severe side effects in patients undergoing therapy.
Under normal circumstances, there are many checkpoints to T-cell activation, the most
prevalent being antigen recognition by the T cell receptor on the surface of an antigen
presenting cell. This paring is very specific, and initiates the T-cell activation cascade.
The T-cell engaging bi-specific antibody bypasses this step of MHC-TCR pairing,
effectively providing every T-cell the agent comes into contact with the therapeutic a new
T-cell receptor recognizing the antigen of interest, initiating a large scale T-cell activation
targeted toward the antigen of interest. This new interaction must be as specific at a
typical MHC-TCR interaction, to prevent antigen-independent wide scale T-cell
activation. One good aspect of this therapeutic is its short serum half-life (max 2hrs in
this bloodstream), which allows the clinician to titrate the dose and discontinue the
treatment quickly should adverse effects occur (37).
To establish the antigen specificity profile of the h8F4 bi-specific antibody, flow
cytometry analysis antibody binding to cell surfaces was conducted. All samples were
stained with a LIVE/DEAD fixable viability dye prior to acquisition. All flow cytometry
data were collected using a BD FACSCanto II flow cytometer, and analyzed with FlowJo
Software version 10.1.
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First, peripheral blood lymphocytes (PBL) were prepared from collecting nonadherent lymphocytes after 1-2 hour’s incubation of peripheral blood mononuclear cells
isolated using Ficoll density centrifugation of buffy coats purchased from MDACC blood
bank. For h8F4 bi-specific antibody binding of CD3, Jurkat, J.RT3 and human PBL were
incubated with various concentrations of h8F4 bi-specific antibody for 45 minutes on ice,
and stained with a secondary anti-HisTag antibody conjugated with PE fluorophore after
washing with PBS. The h8F4 bi-specific antibody showed concentration-dependent
binding to Jurkat cells and healthy donor CD5+ T-cells (Figure 13). Dissociation
constants were calculated using a curve fitting 4-parameter non-linear regression formula.
Dissociation constants (kD) values of 0.75 nM for Jurkat cell surface binding and 0.69
nM CD5+ T-cell binding, but no binding to CD3-mutant Jurkat cell line J.RT3 cells was
detected. This result demonstrates CD3-specific binding capacity of h8F4 bi-specific
antibody.
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Figure 13: Flow cytometry analysis of h8F4 bi-specific antibody binding of CD3+
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Figure 13: Flow cytometry analysis of target binding specificity by h8F4 bi-specific
antibody. Each data point represents the mean of triplicate measures and error bars
represent SEM. Mean fluorescent intensity is reported.

	
  

32

For evaluation of HLA-A2/PR1 binding specificity, TAP-deficient HLA-A2+ T2
cells were pulsed with HLA-A2 restricted peptides PR1 and CMV-pp65 and h8F4 bispecific antibody surface binding was quantified (Figure 14). There was a significant
difference (P=0.0005) in h8F4 bi-specific antibody binding to T2-PR1 (kD = 14.1 nM)
compared to T2-pp65 (kD 20 = uM) using a calculated using a curve fitting 4-parameter
non-linear regression formula to determine kD and a paired two-tailed T-Test to
determine significance. For determination of kD values, top and bottom constraints were
employed based on maximum and minimum MFI. These results indicate the antibody
exhibits HLA-A2/PR1 specific biding to the cell surface, although there is background
recognition of the HLA-A2 molecule, as evidenced by detectable staining to the control
peptide-pulsed HLA-A2/CMV T2 cells. This phenomenon has also been demonstrated
with the parent 8F4 antibody, but has not translated into a meaningful clinical “off-target”
effect in in vivo experiments (24).
Further, multiple AML cell lines were stained with the h8F4 bi-specific antibody.
Results in Figure 14 also showed strong concentration-dependent binding to HLA-A2+
AML cell lines THP1 (kD= 30 nM), U937 A2+ (kD = 2.2 nM), and K562 A2+ (kD = 8.4
nM), but not wild type U937 and K562 (Figure 14). THP1 is an AML cell line with
endogenous HLA-A2 expression and thus does not have an HLA-A2- control.
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Figure 14: Flow cytometry analysis of h8F4 bi-specific antibody binding of HLAA2/PR1

Figure 14: Flow cytometry analysis of h8F4 bi-specific antibody binding of different
AML HLA-A2/PR1+ (T2 PR1, THP1, U937 A2+, K562 A2+) and control (T2 CMV,
U937 WT, K652 WT) cell lines, detected with anti-HisTag PE. Mean fluorescent
intensity is reported. Each data point or bar represents the mean of triplicate measures
and error bars represent SEM.
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To assess similarities between the h8F4 bi-specific antibody and the parent h8F4
monoclonal antibody’s recognition of target complex HLA-A2/PR1, T2 cells were pulsed
with PR1-variant peptides with sequential Alanine substitutions, in addition to PR1 wild
type (VLQELNVTV), WT1 (RMFPNAPYL), MART1 (ELAGIGILTV), and control
HLA-A2 restricted CMV-derived peptide pp65 (NLVPMVATV). Surface staining was
assessed by flow cytometry. To confirm the mutant peptides were in fact presented on the
surface of T2 cells, MFI analysis of the surface HLA-A2 status was performed (data not
shown). It is a known phenomenon with this cell line that peptide pulsing increases the
surface expression of HLA-A2, and results in a shift in HLA-A2 staining when peptidepulsing is effective (33). Results outlined in Figure 15 showed the h8F4 bi-specific
antibody and parent h8F4 antibody have very similar PR1 peptide recognition profiles,
with residues at positions 2, 4, and 9 showing decreased antibody recognition. These
positions represent the amino acids Lysine, Glutamate, and Valine, within the PR1
peptide, respectively. These residues are key for recognition of the HLA-A2/PR1
complex by both antibodies. Alanine substitutions at these positions reduced h8F4 bispecific antibody binding by 90%, 68%, and 88%, respectively. Results also showed
minimal surface recognition of other HLA-A2 restricted peptides MART1 and WT1,
again supporting HLA-A2/PR1 specificity.
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Figure 15: Evaluation of antigen binding similarities between parent h8F4 antibody
and h8F4 bi-specific antibody

Figure 15: Flow cytometry analysis of h8F4 bi-specific antibody and parent h8F4
monoclonal antibody staining of T2 cells pulsed with PR1 peptides containing sequential
alanine substitutions, with PR1, CMV-pp65, WT1, MART1 and un-pulsed T2 controls.
Percent maximum PR1 specific binding is reported.
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Bio-layer Interferometry
h8F4 bi-specific antibody binding kinetics were assayed by Bio-Layer
interferometry (BLI) with a PALL ForteBio Octet 384 RED system (Menlo Park, CA).
For antigen binding, h8F4 bi-specific antibody was AR2G chemically coupled to
biosensor, and then dipped into various concentrations of HLA-A2/PR1 as analyte from
300 nM to 3.7 nM or HLA-A2/CMV-pp65 at 900 nM as control. Monovalent h8F4 F(ab)
and bivalent h8F4 parent antibody antigen binding kinetics were evaluated as a control by
capturing biotinylated HLA-A2/PR1 or pp65 monomers on streptavidin biosensors at a
concentration of 200nM, then soluble h8F4 F(ab) or parent antibody was dipped into
kinetics buffer as analyte at various concentration from 300 nM down to 3.7 nM.
h8F4 bi-specific antibody binding to CD3 was determined using BLI technology
as well. Recombinant human CD3 delta + CD3 epsilon (biotinylated) protein (Abcam
Catalog #ab205994) was captured on a streptavidin sensor chip at a concentration of 200
nM, and h8F4 bi-specific antibody or parent anti-human CD3 (clone OKT3) antibody
were evaluated for binding to immobilized human CD3Ɛδ fusion proteins at different
concentrations. Data analysis was performed using 2:1 global fitting with Octet data
analysis software. Results show the h8F4 bi-specific antibody had strong interactions
with the HLA-A2/PR1 monomer with a calculated kD of 9.7nM, compared to control
HLA-A2/CMV monomer with no reactivity to the h8F4 bi-specific antibody at high
concentrations (Figure 16). The h8F4 bi-specific antibody interaction with HLA-A2/PR1
was comparable to the full-length h8F4 antibody (kD = 6.3nM) and the h8F4 F(ab) (kD =
8.7nM) tested in parallel. Further, the h8F4 bi-specific antibody bound the human CD3
epsilon unit, with a calculated kD of 4.8 uM, as compared the to the bivalent OKT3
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antibody (kD = 137nM). These results support the flow cytometry results demonstrating
h8F4 bi-specific antibody HLA-A2/PR1 and CD3 specificity. These results also compare
to affinity studies of Blinatumomab, with CD19 and CD3 binding affinities measuring
10-9 and 10-7 Molar, respectively (17).
Figure 16: Bio-layer interferometry analysis of h8F4 bi-specific antibody binding

Figure 16: Bio-layer interferometry analysis of h8F4 bi-specific antibody binding to
immobilized (A) HLA-A2/PR1, HLA-A2/CMV monomers and (B) immobilized CD3εδ
fusion protein.
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Anti-idiotype antibody ELISA
Anti-idiotype antibodies recognize and bind antigen-binding domains of
antibodies, typically antibody drugs (38). Here, we used several anti-idiotype antibody
clones specific for h8F4 to assess the antigen-binding domain of h8F4 bi-specific
antibody and parent h8F4 antibody. Standard sandwich ELISA was used to determine
h8F4 bi-specific antibody binding to anti-idiotype antibodies generated against the parent
h8F4 antibody. First, anti-idiotype antibodies coated a 96-well plate at 1µg/mL overnight
at 4oC. After washing unbound anti-idiotype antibodies, h8F4 bi-specific antibody, parent
h8F4 monoclonal antibody, control CD1d protein containing a C-terminal His6Tag (34),
and control trastuzumab monoclonal antibody were incubated for 1 hour at room
temperature (RT). After washing, anti-HisTag HRP was used to detect h8F4 bi-specific
antibody and CD1d protein bound to immobilized anti-idiotype antibodies, and goat antihuman IgG HRP was used for detection of monoclonal antibodies h8F4 and trastuzumab.
TMB substrate activity was measured at OD450 using a Cytation 3 from BioTek and
Fisher Scientific (Pittsburgh, PA).
Figure 17 shows the h8F4 bi-specific antibody showed significantly higher
binding to all 4 anti-idiotype antibody clones as compared to the control CD1d
recombinant protein (determined by T-test for each clone) while the parent h8F4 antibody
showed strong binding to all 4 anti-idiotype clones as opposed to control trastuzumab.
The h8F4-bispecific antibody bound the anti-idiotype clones with lower affinity
compared to the parent antibody, and this may be due to the monovalent interaction of the
bi-specific antibody with it’s target, as opposed to the bivalent interaction of the parent
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h8F4. This data again supports the conclusion that the h8F4 bi-specific antibody and
parent h8F4 antibody recognize the same conformational epitope.
Figure 17: Anti-idiotype ELISA
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Figure 17: Survey of conformational epitopes of antigen binding domain of h8F4 bispecific antibody with anti-idiotype antibody ELISA. O.D. 450 is reported. Significance
was calculated using T-test for each antibody clone.
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Co-culture experiments – AML Cell Lines
In the previous section, we proved the h8F4 bi-specific antibody demonstrates
antigen specific binding to both CD3 and the leukemia antigen HLA-A2-PR1. The next
step in evaluating the therapeutic potential of this antibody was to determine the
antibodies potential to mediate redirected T-cell mediated cytotoxicity towards the target
AML of interest. We first determined the ability of the antibody to activate T-cells, and
next examined of this activation led to detectable AML targeted cytotoxicity.

Flow Cytometry and Cytokine ELISA: T-cell Activation
To evaluate bi-specific antibody-mediated T-cell activation, target AML cell lines
THP1 and U937 (A2+/-) were stained with a pacific blue (PB) CellTracker dye and cocultured with effector PBL at an Effector: Target ratio of 2:1 in complete media with
increasing concentrations of h8F4 bi-specific antibody in a 96 well plate for 18h,
37oC/5% CO2. Following incubation, culture supernatant was harvested for ELISA to
detect secreted IL-6, IL-2, IFN-γ, and TNFα. After incubation cells were also stained for
viability, CD5, CD4, CD8, and CD69. Flow cytometry acquisition was obtained using a
high throughput sampler program on a BD FACSCanto II flow cytometer. For evaluation
of T-cell activation, surface CD69 staining (presented as mean fluorescent intensity) was
quantified on live, PB-, CD4+ and CD8+ T-cells.
Results of these experiments show upon incubation with h8F4 bi-specific
antibody for 18h, healthy donor CD4 and CD8 T-cells had increased surface expression
of the early T-cell activation marker CD69 in a concentration-dependent manner in the
presence of AML cell lines THP1 and U937 (Figure 18). Results also show low levels of
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surface CD69 T-cell activation in T-cells at high h8F4 bi-specific antibody concentration
in the absence of target cells or in the case of U937, in the presence of control U937 A2cells. This is most likely a result of a high concentration of antibody coating the T-cells
leading to auto-activation of the T-cells. This conclusion is supported by the data that
shows the auto T-cell activation decreases to zero, as the concentration of antibody is
decreased, while the activation in the presence of the HLA-A2+ cells remains high.
In addition, activated T-cells produced several cytokines such as IL-6, IL-2, IFNγ, and TNF-α in a concentration-dependent manner. There were no detectable cytokines
in the absence of AML targets (Figure 19). There was no detectable IL-2 production in
the U937 co-culture experiments, and this may have been due to the short incubation time
of 18h. These results support that the h8F4 bi-specific antibody actively engages T-cell
subsets solely in the presence of the HLA-A2+ AML cell line THP1 or U937 A2+
resulting in T-cell activation.
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Figure 18: h8F4 bi-specific antibody induces T-cell activation following co-culture
with THP1 AML cell line
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Figure 18: T-cell activation by h8F4 bi-specific antibody. 18h Co-culture experiments
combining h8F4 bi-specific antibody with effector healthy donor lymphocyte effectors
and target AML cell line THP1 at an Effector:Target ratio of 2:1 were conducted in
triplicate. Flow cytometry assessed surface CD69 of activated T-cells in the presence of
target cells U937 (top) and THP1 (bottom) as compared to control experiments lacking
AML targets.
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Figure 19: Cytokine production following h8F4 bi-specific antibody T-cell activation
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Figure 19: Cytokines from co-culture experiments were quantified by ELISA for IFN-γ,
IL-2, IL-6 , and TNF-α. Unless otherwise indicated, each data point represents the mean
of triplicate measures and error bars represent SEM.
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Cytotoxicity Analysis
Next, we determined h8F4 bi-specific antibody mediated cytotoxicity using flow
cytometry. Target AML cell lines THP1 and U937 (A2+/-) were stained with a pacific
blue (PB) CellTracker dye and co-cultured with effector PBL at an Effector: Target ratio
of 2:1 in complete media with increasing concentrations of h8F4 bi-specific antibody in a
96 well plate for 18h, 37oC/5% CO2. Positive target cell lysis control was prepared with
lysis of AML cells with 0.1% Triton in PBS. After incubation cells were stained for
viability, and CD5. Flow cytometry acquisition was obtained using a high throughput
sampler program on a BD FACSCanto II flow cytometer. Viability of AML cells was
determined with nuclear uptake of live/dead fixable dye. For calculation of h8F4 bispecific mediated cytotoxicity, total cell counts of live target cells (PB+, CD5-) were
compared to control groups, and calculated as follows: % cytotoxicity (CTX) = 100 x
(Target count at 0 nM h8F4 bi-specific antibody – Target count with h8F4 bi-specific
antibody treatment) / (Target count 0 nM h8F4 bi-specific antibody - Target counts with
0.1% triton).
Results presented in Figures 20 and 21 show the h8F4 bi-specific antibody redirected T cell cytotoxicity to lyse THP1 (Figure 20) and U937 A2+ (Figure 21) AML
cells after 18 hours. EC50 values were calculated using a curve fitting 4-parameter nonlinear regression formula. For the cell line THP1, after 18h co-culture up to 50% of target
AML cells had been lysed, resulting in an EC50 value of 41.7 nM. In comparison, up to
40% U937 A2+ cell lysis was detected after 18h, with undetectable changes in the
number of U937 A2- control cells. The calculated EC50 value for U937 A2+ lysis was
229 nM. These results indicate the h8F4 bi-specific antibody has a robust effect on
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redirected AML cell lysis even after a short incubation time and at relatively low h8F4
bi-specific antibody concentrations. These results are comparable to other bi-specific
antibodies in this class, who demonstrate similar % cytotoxicity after only 24h incubation
(13, 38, 39).

Figure 20: Redirected cytotoxicity of T cells against HLA-A2/PR1+ cell line THP1
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Figure 20: Calculated % cytotoxicity based on flow cytometry analysis of live PB+ CD5AML cell counts. Each data point represents the mean of triplicate measures and error
bars represent SEM.
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Figure 21: Redirected cytotoxicity of T-cells towards AML cell line U937
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Figure 21: Calculated % cytotoxicity based on flow cytometry analysis of live PB+ CD5AML cell counts. Each data point represents the mean of triplicate measures and error
bars represent SEM.
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Co-Culture experiments- Primary Patient AML Samples
Similar co-culture experiments were performed with healthy donor allogeneic
PBL and patient AML leukapheresis samples. The HLA testing of patient leukapheresis
was conducted at the MDACC HLA typing laboratory. Prior to use in co-culture
experiments, frozen patient samples were thawed and allowed to recover overnight in
complete medium. Following 18h co-culture with allogeneic healthy donor PBL at a 2:1
Effector:Target ratio, cells were stained for viability, CD5, CD4, CD8, CD69, and
CD33/CD34 and flow cytometry acquisition and control groups were included as
described above. To assess h8F4 bi-specific mediated T-cell activation, surface CD69
expression was calculated for live, CD5+, CD4+, and CD8+ cells. For calculation of h8F4
bi-specific mediated cytotoxicity, total cell counts of live target cells (CD5-, CD8-,
CD33/34+) were compared to control groups, and % CTX was calculated.

Patient Profiles
A table of the AML patient sample profiles used in these experiments has been
included as Table 1. In brief, seven AML patient leukapheresis samples were used for
evaluating h8F4 bi-specific antibody redirected lysis. All patient samples were either
HLA-A2+ or HLA-A2- AML samples. Viability of each sample was assessed prior to use
in the assay, as well as percentage of CD3+ T-cells and CD19+ B-cells, and percentage
of AML CD33/34+ blasts. All samples consisted of >80% live cells. As these samples
were leukapheresis samples, CD3+ and CD19+ lymphocyte percentages were low (< 5%
and < 19%, respectively) and AML CD33+/34+ blast percentage was high (> 79%). A
number of these samples have been evaluated by our group for engraftment in non-obese
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diabetic (NOD) mice with Prkdcscid and Il2rgtm1Wjl mutations (NSG) mice, as indicated in
the last column of the table.
Table 1: Summary of clinical characteristics for AML Patient Samples

Sample

HLA-

Collection

A2

%

%

%

CD3+

CD19+

% CD33/34+

NSG

Name

Cancer

date

status

viability

T-cells

B-cells

AML Blasts

Engraftment

1

AML

20130528

NEG

88

3

1

94

NO

2

AML

20131028

NEG

83

1

0.1

82

3

AML

20110316

NEG

94

1

0.1

95

4

AML

POS

93

0.3

7

94

YES

5

AML

20140327

POS

96

5

3

88

YES

6

AML

20110816

POS

98

2

24

79

YES

7

AML

20150206

POS

89

1.5

0.4

86

NO

Table 1: Clinical summary of AML patient leukapheresis samples for h8F4 bi-specific
antibody co-culture experiments.
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Flow Cytometry for T-cell Activation
First we determined the h8F4 bi-specific antibody’s ability to target and redirect
T-cell cytotoxicity to lyse primary AML blasts. The leukapheresis samples from AML
patients were co-cultured at a 1:2 ratio with healthy resting lymphocytes in the presence
or absence of h8F4 bi-specific antibody for 18h. Both CD4+ and CD8+ T-cells upregulated surface expression of CD69 in the presence of h8F4 bi-specific antibody when
co-cultured with HLA-A2+ AML blasts compared to HLA-A2- AML blasts, or in the
absence of blasts (Figure 22). There was no or very low detectable CD69 in T-cells when
co-cultured with primary AML blasts in the absence of bi-specific antibody, indicating
there was little to no allo-reactivity of the T–cells to the leukemia samples, and all T-cell
activation was mediated by the bi-specific antibody. There was detectable T-cell
activation in the presence of HLA-A2- AML patient samples at this concentration. This
may have been due to the phenomenon described previously, in which T-cells autoactivate each other at high antibody concentrations. Due to the limited availability of the
patient samples, only one concentration was tested. Reducing the concentration of
antibody may reduce this auto-activation.
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Figure 22: h8F4 bi-specific antibody induces T-cell activation following co-culture
with primary AML patient samples
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Figure 22: Summary of T-cell activation for primary patient sample co-culture
experiments showing increased T-cell activation following co-culture with HLA-A2+
patient samples. Unless otherwise indicated, each bar represents the mean of triplicate
measures and error bars represent SEM.
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Cytotoxicity Analysis

Next, AML blasts were stained for viability and % cytotoxicity was calculated to
determine the T-cell redirected cytotoxicity towards the patient samples. Activated Tcells mediated lysis of CD33/34+ AML blasts in an HLA-A2 dependent manner. Results
show the h8F4 bi-specific antibody redirects cytotoxicity of T-cells towards HLA-A2+
primary AML blasts at a concentration of 200pM, but shows minimal cytotoxicity of
HLA-A2- primary leukemia blasts at the same concentration, and an absence of
cytotoxicity in the 0pM bi-specific antibody treatment groups (Figure 23).
Figure 23: h8F4 bi-specific antibody redirects cytotoxicity of T-cells towards HLAA2+ primary AML blasts
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Figure 23: Flow cytometry determined T-cell redirected cytotoxicity against HLA-A2+
and HLA-A2- AML patient samples. Live target AML blasts were identified as
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CD33/34+, fixable live/dead-, CD5-. Each bar represents the mean of triplicate measures
and error bars represent SEM.
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Chapter 6: In vivo functional analysis
Background
After confirming the h8F4 bi-specific antibody successfully targeted AML in a
antigen-specific manner and facilitated redirected T-cell mediated cytotoxicity in vitro, in
vivo experiments were undertaken to further the pre-clinical development of this
therapeutic. Our group has extensive experience with xenograft mouse models utilizing
both AML cell lines and primary patient AML samples (24). Xenograft models of the
AML cell line U937 A2+ were used to initially test the efficacy of the h8F4 bi-specific
antibody. This cell line was chosen as its engraftment in the mouse has been well
characterized by our group, and is considered to an aggressive leukemia model compared
to other AML cell lines. The goal of the experiment was to reduce leukemia burden of
U937 AML and prevent engraftment.
In brief, non-obese diabetic (NOD) mice with Prkdcscid and Il2rgtm1Wjl mutations
(NSG) mice were utilized for these experiments, as these mutations eliminate murine
production of T-cells, B-cells, and NK cells, and following irradiation, provide a niche
for human AML engraftment (40). Following 250 rads of radiation, mice were injected
via tail vein with the U937 HLA-A2+ AML cell line transduced with red-shifted Luciola
Italica luciferase transgene under control of the stable Ubiquitin C promoter. The
luciferase transgene is fused to the GFP gene, enabling detection of the AML cell line via
flow cytometry and bio-luminescence imaging in live animals. The following is a brief
description of the in vivo experiments.
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Materials and treatment schedule
NSG mice were purchased from Jackson Labs and housed at MDACC. 6-10
week old NSG mice were sub-lethally irradiated and injected with 5000 U937A2+ AML
cells via tail vein. AML was allowed to engraft for 3 days, after which 3 million healthy
donor PBMC isolated from fresh buffy coats purchased from MDACC were injected into
designated treatment groups via tail vein. The following day, treatment with the h8F4 bispecific antibody was started, and continued daily for either 7 or 14 days at either 0.5µg
or 1µg daily dose. PBS injections served as both PBMC and bi-specific antibody
treatment control. Summary of treatment groups and treatment schedule are as follows, as
well as in Figure 24:

1: U937A2+ + PBS + PBS (n=5 mice)
2: U937A2+ + PBMC + PBS (n=5 mice)
3: U937A2+ + PBMC + 0.5ug Bi-specific Ab (n=5), 7 days treatment
4: U937A2+ + PBMC + 1ug Bi-specific Ab (n=5), 7 days treatment
5: U937A2+ + PBMC + 0.5ug Bi-specific Ab (n=5), 14 days treatment
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Figure 24: Experimental outline for in vivo evaluation of h8F4 bi-specific antibody
treatment of AML
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Figure 24: Summary of treatment groups and treatment schedule for evaluation of in vivo
activity h8F4 bi-specific antibody (labeled in figure as BITE) against AML cell line
U937A2+ (labeled in figure as UA). Experiment Day 0 = IV injection of AML cell line.
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Results
To asses AML engraftment and therapeutic efficacy against the AML,
bioluminescence imaging (BLI) was performed on all living animals several times a week
up to experiment day 35 (31 days following the initiation of therapy), as well as tail vein
blood draws to assess for peripheral circulation of AML cells with flow cytometry. As of
the writing of this dissertation, this experiment was ongoing, and data presented here is a
summary of data collected to date (experiment day 62). Figure 25 presents a visual
summary of BLI collected over the first three weeks of the experiment, with each column
of mice representing each of the treatment groups. This summary shows that in
comparison to the control groups that did not receive any h8F4 bi-specific antibody
therapy, the three treatment groups that did receive treatment remain AML free, based on
BLI imaging. AML growth with BLI imaging was assessed for several weeks following
the final bi-specific antibody treatment, and quantification of bio-luminescence collected
thus far is presented in Figure 26.
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Figure 25: Visual summary of bio-luminescence data for first 21 days of in vivo
experiment

Figure 25: Visual summary of BLI collected over the first three weeks of the experiment,
with each column of mice representing each of the treatment groups.
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Figure 26: Quantitative assessment of U937A2+ AML engraftment as assessed by
bio-luminescence imaging following h8F4 bi-specific antibody treatment
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Figure 26: Summary of BLI data collected for evaluation of in vivo activity h8F4 bispecific antibody. Days represent the number of days following injection of U937 AML
cell line.
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This data shows several important key findings. First, there is no significant
difference between the control U937A2+ + PBS + PBS and U937A2+ + PBMC + PBS
groups, indicating the majority if not all of the T-cell mediated cytotoxicity in the h8F4
bi-specific antibody treatment groups is mediated via the antibody and not as an alloreactive T-cell response towards the AML cells. Second, differences in treatment dose do
not become apparent until 2+ weeks following the last dose of h8F4 bi-specific antibody.
Comparison between 7 days of treatment with either 0.5µg/day and 1µg/day h8F4 bispecific antibody indicate AML engraftment is reduced in both groups until day 25, after
which AML engraftment increases in the 1µg/day treatment group at a much faster rate
than the 0.5µg/day treatment group. This is surprising, as we would expect the h8F4 bispecific antibody treatment to be dose dependent, with higher doses translating to better
control of AML engraftment. This difference in treatment outcome may be due to T-cell
exhaustion, as the high dose of h8F4 bi-specific antibody may be providing a robust but
short-lived T-cell activation. Figure 27 shows percent peripheral blood T-cells from
experiment day 29, assayed by flow cytometry. This data indicates the percentage of
circulating T-cells is comparable between the 0.5µg/day and 1µg/day treatment groups.
Assessment of the activity of these T-cells has not been evaluated. Determining the
activation status of these T-cells may provide information about their functionality and
cytotoxic potential, and may provide evidence as to why the U937A2+ AML cells were
able to successfully engraft in the 1µg/day treatment group.
As a comparison, in previous experiments characterizing the U937 AML
xenograft model, treatment with the h8F4 antibody (10mg/kg, 3 times a week for 10 total
doses) showed reduced leukemia engraftment for one week following conclusion of
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therapy. Unfortunately this experiment was not carried out for survival measurement, and
the animals were sacrificed and tissues were examined for AML engraftment. Figure 28
shows the bio-luminescence measurement of AML cells up until the day the animals
were sacrificed following treatment with the parent h8F4 antibody. Assessment of the
final leukemia burden of these animals showed significant protection against U937 AML
engraftment with h8F4 therapy, although it appears engraftment may have begun at the
time of sacrifice, as there is a slight rise in peripheral blood AML cells see via flow
cytometry (Figure 29). No other tissues showed detectable AML cells.
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Figure 27: Percentage of peripheral T-cells following h8F4 bi-specific antibody
treatment

Figure 27: Flow cytometry assessment of tail vein blood from in vivo experiment day 29.
Circulating T-cells (CD45+, HLA-A2-, GFP-, CD3+) were quantified across all treatment
groups. All groups administered PBMC at the start of the experiment had comparable
percentages of circulating T-cells.
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Figure 28: Quantitative assessment of U937A2+ AML engraftment as assessed by
bio-luminescence imaging following h8F4 antibody treatment.
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Figure 28: Summary of BLI data collected for evaluation of in vivo activity h8F4
antibody therapy. Days represent the number of days following injection of U937 AML
cell line.
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Figure 29: Flow cytometry analysis of U937 AML engraftment following h8F4
antibody therapy.
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Figure 29: Flow cytometry analysis of U937 AML cell line engraftment following h8F4
treatment, as assessed by % human CD45+, GFP+ cells in the peripheral blood.
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Another aspect of this experiment evaluated differences in treatment duration,
comparing 7 days versus 14 days of 0.5µg/day h8F4 bi-specific antibody therapy. Results
of the experiment thus far indicate there is a difference between the two treatment
strategies, as the 14-day treatment group looks to have a survival advantage based on
Kaplan-Meier survival estimates provided in Figure 30. As of the writing of this
dissertation, mice in the 14 day treatment group showed minimal signs of U937 A2+
AML engraftment based on BLI and flow cytometry, and remain healthy and leukemia–
free 40+ days following the last h8F4 bi-specific antibody dose. In comparison, three
mice from the 7-day treatment group have succumbed to disease. These results are
expected, as long treatment schedules are standard of care for patients receiving
Blinatumomab therapy in the clinic. These patients receive continuous infusions of
therapy for 4 weeks at a time, for several cycles in a row, to ensure continuous antibody
levels and sustained T-cell activation and redirected cytotoxicity (17).
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Figure 30: Kaplan-Meier survival estimate for in vivo treatment with h8F4 bispecific antibody.
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Figure 30: Kaplan-Meier survival curve based on data as of experimental day 50. Median
survival estimates are provided at the bottom of the figure, showing treatment with the
h8F4 bi-specific antibody confers a survival advantage following U937 AML
engraftment.
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Chapter 7: Discussion and Future Directions
Recent advances in the field of cancer immunotherapy prove the immune system
is a critical component for the treatment of cancer. This report presents the development,
in vitro characterization, and initial in vivo characterization of a therapeutic for the
treatment of HLA-A2/PR1+ malignancies. First, we showed successful eukaryotic
expression and purification of the h8F4 bi-specific antibody. Specific target antigen
recognition was demonstrated towards both CD3 and HLA-A2/PR1 through a variety of
methods. Next, the bi-specific antibody showed robust redirected T-cell engagement and
cytotoxicity towards HLA-A2/PR1+ AML cell lines and primary AML blasts at
picomolar concentrations, as evidenced by surface T-cell activation marker CD69,
detectable cytokine release, and AML cytotoxicity following just 18 hours of co-culture.
Of note, T-cells were activated in the absence of target antigen at high concentrations of
bi-specific antibody, but this phenomenon can most likely be attributed to the high
concentration of antibody, leading to CD3 surface saturation and resultant cross-linking
of surface CD3 and activation. This conclusion is supported by data that show as the
concentration of h8F4 bi-specific antibody is reduced, the non-specific T-cell activation
is reduced or eliminated, while antigen-specific T-cell activation is maintained.
In general, in vitro results for the h8F4 bi-specific antibody are similar to those
presented by others in this molecular class (18, 19). The h8F4 bi-specific antibody joins
this class of bi-specific CD3-engaging antibodies to broadly activate T-cells in an
antigen-specific manner, resulting in a safe and relatively targeted therapeutic for the
treatment of cancer. The potency of the h8F4 bi-specific antibody is high, as low
Effector: Target ratios and picomolar antibody concentrations produce detectable cancer

	
  

67

cytotoxicity. This is comparable to others in this class of therapeutics (15, 18), and has
proven to be adequate for successful treatment of patients (17).
The h8F4 bi-specific antibody showed marked cytotoxicity at low Effector:
Target ratios against primary AML blasts, indicating this therapeutic may be effective in
patients with low lymphocyte counts and high leukemia burdens. Recent studies
examining the bi-specific engager AMG 330 targeting the leukemia antigen CD33 (13)
concluded that, as expected, the in vitro activity of this agent correlated with the number
of autologous T-cells present in patient leukemia samples, and effective autologous T-cell
redirected lysis could be detected at Effector: Target ratios as low as 1:>2,700.
Interestingly, for reasons yet to be identified, patients with newly-diagnosed AML were
more responsive to therapy than those with relapsed/refractory disease (41).
To support the utility of this therapeutic for early treatment of AML, reports have
shown that loss of HLA is an immune escape mechanism in AML, primarily following
hematopoietic stem cell transplantation (42, 43). As the h8F4 bi-specific antibody targets
a leukemia-associated antigen dependent on the expression of HLA, the bi-specific
antibody would lose effectiveness in these patients. Clinical studies of the CD19 bispecific antibody have also demonstrated relapses following treatment with their
therapeutic, with approximately 10-15% of patients relapsing with CD19- ALL. These
are important considerations for further clinical development of the antibody. Results of a
current clinical trial investigating the effectiveness of Blinatumomab in the treatment of
newly-diagnosed ALL as a first line therapy may be indicative of how well this class of
therapeutics handles disease in combination with conventional chemotherapy, as opposed
to following standard induction therapy (17).
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In addition, it has been reported that AML patients with high absolute lymphocyte
counts at the time of diagnosis have a decreased remission period and overall survival,
possibly due to a high number of regulatory T-cells in these patients (44). Although not
directly tested here, our antibody may have the ability to overcome this dysfunctional
component of the AML patients’ immune system and target regulatory cells and convert
them to functional cancer-fighting immune cells, as other antibodies in this class have
demonstrated the ability to activate regulatory T-cells (37, 45).
Our h8F4 bi-specific antibody shares many characteristics with the T-cell
engaging bi-specific antibody class of therapeutics, making it a strong candidate for the
future treatment of HLA-A2+ AML. Previously, we have also shown that HLA-A2/PR1
is present on certain solid tumors such as breast and lung cancer (46-48) via the
mechanism of cross-presentation. This further expands a spectrum of diseases that may
be treated with the h8F4 bi-specific antibody.
Further, this bi-specific antibody represents the second in a unique class of bispecific T-cell engagers, in which the cancer-targeting region functions as a TCR-mimic,
simultaneously recognizing the HLA molecule and its presented peptide. Another bispecific antibody, the ESK1-BiTE, targeting the RMF peptide RMFPNAPYL produced
from the intracellular oncogenic Wilms Tumor protein WT1 (49), has shown great
promise in the treatment of several different malignancies in vivo, and demonstrated a
novel mechanism in which the bi-specific antibody recruits and activates autologous preexisting T-cells in patients (19). In their report, the ESK1-BiTE generated a T-cell
response in an ovarian cancer patient targeting the HER2/Neu cancer antigen, an antigen
not directly targeted by the ESK1-BiTE. The authors hypothesize this is a re-activation of
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pre-existing T-cells targeting the HER2/Neu antigen, and this reactivation may be due to
the close proximity facilitated by the bi-specific antibody and the tumor. It would be key
to investigate this phenomenon further with both traditional bi-specific T-cell engagers
and this sub-class of TCR-like bi-specific antibodies that target HLA-A2/peptide
antigens. In general, those TCR-like antibodies developed thus far have higher target
affinity compared traditional antibody therapeutics (23, 24). To our knowledge, this
epitope spreading response following ESK1-BiTE engagement may be unique to TCRlike bi-specific antibodies as a function of their unique binding characteristics, which is
why investigating if this phenomenon occurs with the h8F4 bi-specific antibody and other
bi-specific T-cell engagers would be warranted.
Bio-layer interferometry demonstrated the h8F4 bi-specific antibody’s CD3
affinity was lower than its HLA-A2/PR1 affinity, although these results were not
supported by in vitro analysis of bi-specific antibody binding to CD3 on the cell surface.
This may have been due to the CD3 fusion protein used for the bio-layer interferometry
experiments, as the recombinant human CD3 delta + CD3 epsilon protein is not a
functional CD3 unit, and binding properties to this fragment may not be representative of
true h8F4 bi-specific antibody CD3 binding affinity. Further evaluation, possibly with an
alternative CD3 recombinant protein, is warranted.
If the h8F4 bi-specific antibody does in fact have lower CD3 binding affinity
compared to it’s leukemia targeting moiety, it may be a benefit to its safety profile in
patients, as studies with other bi-specific antibodies targeting the breast cancer antigen
HER2 demonstrated that high affinity CD3 binding may have a negative impact on the
distribution of CD3-targeting bi-specific antibodies to the site of the tumor, and instead
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encourages distribution to regions of the body high in CD3, i.e. lymph nodes (50). Lower
affinity CD3 binding would serve two benefits, first by preventing localization of bispecific antibody-bound T-cells to secondary lymphoid regions instead of to the site of
the tumor where cytotoxicity is preferred, and also, as our studies suggest, preventing
auto-reactive T-cell activation at high concentrations of antibody. Further investigation
into the tissue distribution of the h8F4 bi-specific antibody is needed to further this
potential therapeutic to the clinic. This could be accomplished in vivo as others have
done tracking tumor cells and T-cells with different luciferase genes resulting in different
colors detected during bio-luminescence imaging (19).
The results of the initial in vivo experiments are encouraging. Anecdotal data
from others in our group who have tested the full-length antibody in this U937A2+
xenograft model system have stated the full-length antibody has not shown this length of
durable remission from U937 A2+ engraftment following treatment, although survival
studies have not been conducted per se. Further experiments are needed to confirm these
in vivo h8F4 bi-specific antibody results. For the experiments described here, the
expected effect size was unknown, and thus a small sample size was selected for the pilot
study. Results of these experiments show that repeating the experiment would produce a
large effect, and thus this can be taken into account with further in vivo experiment
planning. The most accurate way to determine the sample size for repeating the in vivo is
to assume at least a medium effect size between the bi-specific antibody group and the
untreated group, or 50% effect size. Power analysis methods should be used to determine
sample size, which takes into account effect size, expected standard deviations within
each group, type 1 error, power, direction of the effect, and animal attrition. (51). All of
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these points can be estimated to arrive at a sample size that will provide accurate answers
to our question without wasting resources.
In addition, basic pharmacokinetic experiments examining the serum half-life of
the bi-specific antibody need to be conducted. As data from this report shows, the antiidiotype antibody ELISA could be used for detection of the h8F4 bi-specific antibody in
the serum, a commonly used technique used for antibody drug detection (52). The halflife would be expected to be low, as FDA-approved Blinatumomab has a serum half-life
of less than 2 hours (17). Finally, a direct comparison in AML reduction following
parallel h8F4 bi-specific antibody and parent h8F4 therapy is needed to conclude whether
these therapeutics have similar efficacy. As these two therapies have different modes of
action, it would be reasonable to think that they could be used in tandem, depending on
the patient’s clinical status and the status of their immune system. For example, the
mechanism of action for the parent 8F4 antibody requires the presence of NK cells to
carry out antibody-dependent cellular toxicity. In contrast, the bi-specific antibody only
needs T-cells for AML cytotoxicity. These are two very different immune system
requirements, and thus each therapy may have utility in the course of a patient’s disease.
This treatment scheme would also depend on why the first HLA-A2/PR1 targeting
therapy failed, as loss of HLA expression would warrant either treatment ineffective.
It would also be interesting to examine tissue from animals that fail treatment in
each group and compare their engraftment characteristics. As described previously,
treatment of patient primary xenograft AML models with the 8F4 antibody ultimately
fails due to AML escape to the CNS, where it is assumed the antibody cannot penetrate.
Studies with other bi-specific T-cell engaging antibodies have shown successful
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treatment of glioblastoma multiforme in the brain, although mechanisms for how this was
accomplished (antibody penetration of the blood brain barrier v. migrating T-cell coated
with antibody) were not defined. This possible tissue penetration may provide an
advantage over the parent antibody therapy, but further in vivo studies are needed to
confirm this hypothesis.
In summary, our data demonstrated that h8F4 bi-specific antibody exhibits potent
antigen-specific redirected T-cell cytotoxicity against HLA-A2+ AML, and could
potentially contribute to advances in therapeutic options for patients in desperate need of
effective therapies. Further investigation into the effects of this therapy in vivo are needed
to ensure patient safety, but we are confident this therapeutic has the potential to
contribute to the growing number of therapeutic options for AML patients.
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